{
  "first_published_at": "2014-02-12", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON377644", 
  "title": "Cetuximab: importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 39, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Cetuximab: importance of establishing wild type <em>RAS</em> (<em>KRAS</em> and <em>NRAS</em>) status before treatment of metastatic colorectal cancer</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with <em>RAS</em> mutations (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) who received cetuximab in combination with FOLFOX4 (oxaliplatin-containing) chemotherapy versus FOLFOX4 alone. Cetuximab is now indicated for the treatment of people with epidermal growth factor receptor (EGFR)-expressing, <em>RAS </em>wild-type metastatic colorectal cancer in combination with irinotecan or oxaliplatin based chemotherapy or as a single agent. Evidence of wild type <em>RAS</em> status at these exons is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer. Cetuximab combined with oxaliplatin-containing chemotherapy is now contraindicated in people with metastatic colorectal cancer who have mutant <em>RAS</em> at these exons or unknown <em>RAS</em> status</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Cetuximab (Erbitux) is a treatment for people with metastatic colorectal cancer.</p>\n\n<p>New safety information has become available from a retrospective subset analysis of data from a randomised, multicentre phase II study (OPUS trial EMR 62202-047<cite>Bokemeyer C, et al. J Clin Oncol 2009; 27: 663&#8211;71</cite>) of cetuximab plus (oxaliplatin-containing) FOLFOX4 chemotherapy versus FOLFOX4 alone in people with previously untreated metastatic colorectal cancer. The OPUS trial included 337 people, 179 of whom had wild type <em>KRAS</em> exon 2 tumour status; incidence of additional <em>RAS</em> mutations (at <em>NRAS</em> exons 2, 3 and 4, and at <em>KRAS</em> exons 3 and 4) in this subset was 30&#8226;5%.</p>\n\n<p>People with <em>RAS</em> mutations who were randomly assigned cetuximab plus FOLFOX4 had inferior survival, progression-free survival and objective response rates than did those assigned FOLFOX4 alone. Safety evaluations showed no new findings attributable to cetuximab when comparing wild type and mutated <em>RAS</em> populations: the inferior outcome was due to lack of efficacy in combination with the known toxicity profile as outlined in the product information.</p>\n\nEvidence of wild type <em>RAS</em> status at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em> is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer. Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is now contraindicated in people with metastatic colorectal cancer who have mutant <em>RAS</em> (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) or unknown <em>RAS</em> status. \n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals</strong></p>\n\n<ul>\n<li>Evidence of wild type <em>RAS</em> status (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer</li>\n\n<li>Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is contraindicated in all people with metastatic colorectal cancer who have mutant or unknown <em>RAS</em> status</li>\n\n<li><em>RAS</em> mutation status should be determined by an experienced laboratory using a validated test method</li>\n\n<li>Prescribing information for cetuximab in the treatment of people with squamous-cell carcinoma of the head and neck is not changed by the new information from this analysis</li>\n</ul>\n</div>\n\n<p><strong>Further Information</strong></p>\n\n<p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026\" target=\"_blank\">letter sent to healthcare professionals</a> in January 2014</p>\n\n<p>See <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_med_000769.jsp&#38;mid=WC0b01ac058001d124\" target=\"_blank\">cetuximab product information</a></p>\n\n<p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314896\" target=\"_blank\">similar advice issued for panitumumab (Vectibix)</a> in September 2013</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 7, February 2014: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Cetuximab (Erbitux) is a treatment for people with metastatic colorectal cancer.</p>\n\n<p>New safety information has become available from a retrospective subset analysis of data from a randomised, multicentre phase II study (OPUS trial EMR 62202-047<cite>Bokemeyer C, et al. J Clin Oncol 2009; 27: 663&#8211;71</cite>) of cetuximab plus (oxaliplatin-containing) FOLFOX4 chemotherapy versus FOLFOX4 alone in people with previously untreated metastatic colorectal cancer. The OPUS trial included 337 people, 179 of whom had wild type <em>KRAS</em> exon 2 tumour status; incidence of additional <em>RAS</em> mutations (at <em>NRAS</em> exons 2, 3 and 4, and at <em>KRAS</em> exons 3 and 4) in this subset was 30&#8226;5%.</p>\n\n<p>People with <em>RAS</em> mutations who were randomly assigned cetuximab plus FOLFOX4 had inferior survival, progression-free survival and objective response rates than did those assigned FOLFOX4 alone. Safety evaluations showed no new findings attributable to cetuximab when comparing wild type and mutated <em>RAS</em> populations: the inferior outcome was due to lack of efficacy in combination with the known toxicity profile as outlined in the product information.</p>\n\nEvidence of wild type <em>RAS</em> status at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em> is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer. Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is now contraindicated in people with metastatic colorectal cancer who have mutant <em>RAS</em> (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) or unknown <em>RAS</em> status. \n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals</strong></p>\n\n<ul>\n<li>Evidence of wild type <em>RAS</em> status (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer</li>\n\n<li>Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is contraindicated in all people with metastatic colorectal cancer who have mutant or unknown <em>RAS</em> status</li>\n\n<li><em>RAS</em> mutation status should be determined by an experienced laboratory using a validated test method</li>\n\n<li>Prescribing information for cetuximab in the treatment of people with squamous-cell carcinoma of the head and neck is not changed by the new information from this analysis</li>\n</ul>\n</div>\n\n<p><strong>Further Information</strong></p>\n\n<p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026\" target=\"_blank\">letter sent to healthcare professionals</a> in January 2014</p>\n\n<p>See <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_med_000769.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">cetuximab product information</a></p>\n\n<p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314896\" target=\"_blank\">similar advice issued for panitumumab (Vectibix)</a> in September 2013</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 7, February 2014: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-02-01", 
  "date_last_modified": "2014-02-13", 
  "_assets": [], 
  "_item_id": 39, 
  "summary": "In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations (at exons 2, 3, and 4 of KRAS and NRAS) who received cetuximab in combination with FOLFOX4 (oxaliplatin-containing) chemotherapy versus FOLFOX4 alone. Cetuximab is now indicated for the treatment of people with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan or oxaliplatin based chemotherapy or as a single agent. Evidence of wild type RAS status at these exons is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer. Cetuximab combined with oxaliplatin-containing chemotherapy is now contraindicated in people with metastatic colorectal cancer who have mutant RAS at these exons or unknown RAS status", 
  "body": "Article date: February 2014\n\nCetuximab (Erbitux) is a treatment for people with metastatic colorectal cancer.\n\nNew safety information has become available from a retrospective subset analysis of data from a randomised, multicentre phase II study (OPUS trial EMR 62202-047[^1]) of cetuximab plus (oxaliplatin-containing) FOLFOX4 chemotherapy versus FOLFOX4 alone in people with previously untreated metastatic colorectal cancer. The OPUS trial included 337 people, 179 of whom had wild type KRAS exon 2 tumour status; incidence of additional RAS mutations (at NRAS exons 2, 3 and 4, and at KRAS exons 3 and 4) in this subset was 30•5%.\n\nPeople with RAS mutations who were randomly assigned cetuximab plus FOLFOX4 had inferior survival, progression-free survival and objective response rates than did those assigned FOLFOX4 alone. Safety evaluations showed no new findings attributable to cetuximab when comparing wild type and mutated RAS populations: the inferior outcome was due to lack of efficacy in combination with the known toxicity profile as outlined in the product information.\n\nEvidence of wild type RAS status at exons 2, 3, and 4 of KRAS and NRAS is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer. Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is now contraindicated in people with metastatic colorectal cancer who have mutant RAS (at exons 2, 3, and 4 of KRAS and NRAS) or unknown RAS status. \n\nAdvice for healthcare professionals  \n  \n  * Evidence of wild type RAS status (at exons 2, 3, and 4 of KRAS and NRAS) is required before initiating treatment with cetuximab alone or in combination with chemotherapy in metastatic colorectal cancer  \n  * Cetuximab combined with oxaliplatin-containing chemotherapy (eg, FOLFOX4) is contraindicated in all people with metastatic colorectal cancer who have mutant or unknown RAS status  \n  * RAS mutation status should be determined by an experienced laboratory using a validated test method  \n  * Prescribing information for cetuximab in the treatment of people with squamous-cell carcinoma of the head and neck is not changed by the new information from this analysis  \n  \nFurther Information\n\nSee [letter sent to healthcare professionals](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026) in January 2014\n\nSee [cetuximab product information](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_med_000769.jsp&mid=WC0b01ac058001d124)\n\nSee [similar advice issued for panitumumab (Vectibix)](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314896) in September 2013\n\nArticle citation: Drug Safety Update volume 7 issue 7, February 2014: A1.\n\n[^1]: Bokemeyer C, et al. J Clin Oncol 2009; 27: 663–71\n"
}